PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African American.
CC   HLA typing: A*11:01,11:01; B*49:01,58:05; C*07:01,07:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; HGNC:2731; DDR2; Simple; p.Asn373del (c.1117_1119del); Zygosity=Heterozygous (Cosmic-CLP=925341; DepMap=ACH-000789).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Homozygous (Cosmic-CLP=925341; DepMap=ACH-000789).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=81.52%; Native American=0.47%; East Asian, North=4.23%; East Asian, South=0%; South Asian=0%; European, North=6.51%; European, South=7.26% (PubMed=30894373).
CC   Discontinued: KCLB; 90810; probable.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): ATCC=CRL-5816; Cosmic-CLP=925341; PubMed=25877200
ST   Amelogenin: X,Y (ATCC=CRL-5816; Cosmic-CLP=925341)
ST   Amelogenin: Y (PubMed=25877200)
ST   CSF1PO: 10
ST   D13S317: 12,13
ST   D16S539: 9
ST   D18S51: 12,18
ST   D19S433: 13,14
ST   D21S11: 29
ST   D2S1338: 22
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 11,14
ST   FGA: 25,26
ST   Penta D: 2.2,10
ST   Penta E: 11
ST   TH01: 7,9
ST   TPOX: 10,11
ST   vWA: 15,16
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 39
//
E., Maiorana L., Vasta V., Pezzino F.M., Sunkara S., Wynne K.,
RA   Elia G., Marincola F.M., McCubrey J.A., Libra M., Travali S., Kane M.;
RT   "Characterization of human melanoma cell lines and melanocytes by
RT   proteome analysis.";
RL   Cell Cycle 10:2924-2936(2011).
//
col. 28:461-464(1991).
//
hatic vessel endothelial hyaluronan receptor 1.";
RL   Cancer Sci. 109:3171-3182(2018).
//
ussell E., Johnson B., Buchhagen D.L., Bodner S.M., Phelps R.M.,
RA   Gazdar A.F., Minna J.D.;
RT   "High frequency of somatically acquired p53 mutations in small-cell
RT   lung cancer cell lines and tumors.";
RL   Oncogene 7:339-346(1992).
//
Med=9817906; DOI=10.1128/jcm.36.12.3718-3720.1998; PMCID=PMC105273;
RA   Schultz-Cherry S., Dybdahl-Sissoko N., McGregor M., Hinshaw V.S.;
RT   "Mink lung epithelial cells: unique cell line that supports influenza
RT   A and B virus replication.";
RL   J. Clin. Microbiol. 36:3718-3720(1998).
//
omi M., Goto S.;
RT   "Correction to: Aurora B kinase as a therapeutic target in acute
RT   lymphoblastic leukemia.";
RL   Cancer Chemother. Pharmacol. 88:1055-1056(2021).
//